NCT06945419CompletedPhase 1
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
A Single-Dose and Multiple-Ascending Dose Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 19 Aug 2026
Brief summary (registry, in English)
The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 10 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 219 (actual)
- First submitted
- 18 Apr 2025
- Start date
- 23 Apr 2025
- Primary completion date
- 5 Aug 2026
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT06945419
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 219
- From 23 Apr 2025 to the primary completion date, 5 Aug 2026
- 5 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have had an acute cardiovascular condition within the past 6 months prior to screening
- Have used medications for weight loss within the 3 months prior to screening
- Parts A, B, C, E:
Other illness
- Have liver disease or pancreatitis
- Have any form of diabetes
- Part D:
- Have type 1 diabetes
Who the study is looking for
- Have no significant body weight change for the 3 months prior to screening
- Part A and Part E:
- Are considered healthy
- Have a body mass index (BMI) of 22 to 35 kilograms per square meter (kg/m2) at screening
- Part B:
- Have a BMI of 27 to 45 kg/m2 at screening
- Part C:
- Have a BMI of 25 to 45 kg/m2 at screening
- Part D:
- Have type 2 diabetes
- Have hemoglobin A1C (HbA1c) ≥6.5% and ≤10.5% at screening
- Have a BMI of 27 to 45 kg/m2 at screening
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lilly Centre for Clinical Pharmacology Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
| Fortrea Clinical Research Unit Coordinator of this site? Confirm its status | Dallas | United States | Unknown status |
| Fortrea Clinical Research Unit Coordinator of this site? Confirm its status | Daytona Beach | United States | Unknown status |
| Clinical Pharmacology of Miami Coordinator of this site? Confirm its status | Miami | United States | Unknown status |
| Endeavor Clinical Trials Coordinator of this site? Confirm its status | San Antonio | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.